A 5-year study found that Endoscopic Sleeve Gastroplasty (ESG) as a standalone treatment is safe and effective for weight loss and managing obesity-related conditions like diabetes. Over 66% of patients achieved diabetes resolution, and 54% lost over 10% of their body weight. The study suggests that ESG's benefits for glycemic control are sustained for up to 5 years.
Endoscopic sleeve gastroplasty as a standalone treatment is a safe and effective minimally invasive therapy that could help achieve significant long-term weight loss and sustained improvements inResearchers conducted a 5-year prospective cohort study to evaluate the long-term effects of ESG as monotherapy on obesity-related comorbidities in 404 adult patients with a body mass index ≥ 30 or ≥ 27 with comorbidities who underwent the procedure between August 2013 and July 2024.
Participants had failed prior nonsurgical weight loss attempts or chose not to undergo surgery despite being eligible for it.< .001), with 66.7% patients achieving resolution of diabetes. Similar reductions in A1c levels were observed in the subgroup of patients with prediabetes or diabetes , with 54% of patients achieving a total body weight loss of more than 10%.
This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.All material on this website is protected by copyright, Copyright © 1994-2025 by WebMD LLC. This website also contains material copyrighted by 3rd parties.
Obesity Diabetes Endoscopic Sleeve Gastroplasty Weight Loss Minimally Invasive Surgery
United States Latest News, United States Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Endoscopic Sleeve Gastroplasty Combined With Lifestyle Changes Improves Liver Health and Weight Loss in Patients With MASH and ObesityA study found that endoscopic sleeve gastroplasty (ESG) combined with lifestyle changes led to significant weight loss and improvements in liver health for patients with metabolic dysfunction-associated steatohepatitis (MASH) and obesity over 72 weeks.
Read more »
Vedolizumab Prevents Postoperative Endoscopic Recurrence of Crohn's Disease After Ileocolonic ResectionThe REPREVIO trial found that treatment with vedolizumab within 4 weeks of ileocolonic resection was superior to placebo in preventing postoperative endoscopic recurrence of Crohn's disease in patients with at least one risk factor for recurrence, such as smoking, perforating complications, previous TNF antagonist exposure, or prior resections.
Read more »
Best Long-Sleeve Bodysuits for Winter LayeringThis article recommends the best long-sleeve bodysuits for winter layering, highlighting their features, benefits, and where to purchase them.
Read more »
Latter-day Saint Women Celebrate Cap Sleeve Change, but Deeper Issues RemainThe removal of the cap sleeve from Latter-day Saint women's temple garments has sparked mixed reactions. While some rejoice in the change, others grapple with the long-standing issues caused by the garments, including health concerns and a lack of transparency from the church regarding their history and purpose.
Read more »
ESG Losing its Shine: Survey Reveals Investor HesitationA new survey reveals a decline in investor focus on ESG (environmental, social, and governance) factors, with many citing short-term performance concerns and 'ESG fatigue'. Despite this, investors remain confident in companies' ability to meet sustainability targets.
Read more »
House Judiciary Committee sends letters to investment firms tied to 'woke ESG cartel'Net Zero Asset Managers says that its initiative has attracted some 325 signatories managing $57.5 trillion globally, according to its website.
Read more »